We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Silenced Gene May Treat Cancer

By Biotechdaily staff writers
Posted on 25 Oct 2005
Restoring a gene often silenced in lung cancer causes the cells to self-destruct, suggesting a new strategy for treating the disease. More...


Researchers focused on a gene known as WWOX, which is silenced in a large majority of lung cancers as well as in cancers of the breast, ovary, prostate, bladder, esophagus, and pancreas. In both laboratory and animal experiments, restoring the silenced WWOX gene slowed or stopped the cells' growth. These findings were published in the October 13, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences.

WWOX is a tumor-suppressor gene. The WWOX protein is missing in cells making up many lung tumors, and in 62% of cases, the gene is turned off by a chemical process known as methylation. In the current study, researchers used three different lines of laboratory-grown lung-cancer cells that were missing WWOX protein. They engineered a virus to carry working copies of the WWOX gene into the three cell lines. After five days, cells having an active WWOX gene died, self-destructed by apoptosis. In contrast, the lung cancer cells that lacked the WWOX gene continued growing and increased in number nearly five-fold or six-fold.

The researchers also took some lung-cancer cells to which they had added working copies of the WWOX gene and transplanted the cells into mice. A group of control mice received lung-cancer cells without the WWOX gene. After 28 days, the mice that received tumor cells with no WWOX gene had developed tumors. Of the mice that received tumor cells with the gene, 60% in one group and 80% in another group showed no tumors.

"Our study is a proof of principle,” said co-author Kay Huebner, professor of molecular biology, immunology, and medical genetics at the Comprehensive Cancer Center at Ohio State University (OSU, Columbus, USA).

"We don't believe that using WWOX as a therapy will necessarily eradicate tumors,” added first author Muller Fabbri, a postdoctoral fellow at OSU, "but we do believe that this kind of gene therapy might be useful when used in combination with chemotherapy and other therapies.”



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.